
Matthew Saul Goldberg MD
Dermatopathology
Medical Director, Castle Biosciences Assistant Clinical Professor, Dermatology, The Mount Sinai Hospital
Join to view full profile
5 E 98th StFl 5New York, NY 10029
Phone+1 212-241-9728
Dr. Goldberg is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Dermatopathology, 2014 - 2015
University of California (San Francisco)Residency, Dermatology, 2011 - 2014
Maimonides Medical CenterInternship, Internal Medicine, 2010 - 2011
Icahn School of Medicine at Mount SinaiClass of 2010
Certifications & Licensure
AZ State Medical License 2024 - 2028
NY State Medical License 2016 - 2028
CA State Medical License 2011 - 2027
MA State Medical License 2024 - 2027
PA State Medical License 2024 - 2026
NJ State Medical License 2017 - 2021
DC State Medical License 2015 - 2018
American Board of Dermatology Dermatology
American Board of Dermatology Dermatopathology- Join now to see all
Publications & Presentations
PubMed
- Response to Baharuddin et al.'s Comment on ''The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermat...Matthew S Goldberg, Mark G Lebwohl
Journal of the American Academy of Dermatology. 2026-11-01 - Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcin...Désirée Ratner, Gaurav Singh, Jason M Rizzo, Harrison Nguyen, Aaron S Farberg
Journal of the American Academy of Dermatology. 2026-08-24 - 2 citationsThe 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial.Jonathan I Silverberg, Lawrence F Eichenfield, April W Armstrong, Jerry Bagel, Ben Lockshin
Journal of the American Academy of Dermatology. 2026-06-01
Press Mentions
Castle Biosciences Launches Test to Guide Atopic Dermatitis Treatment SelectionNovember 12th, 2025
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic DermatitisNovember 3rd, 2025
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with MelanomaDecember 12th, 2024
Professional Memberships
- Member
- American Society of DermatopathologyMember
- International Society of DermatopathologyMember
Other Languages
- Spanish, Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:

